Humanized hK2 Antibody Targeting for Prostate Micrometastases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for prostate cancer, such as surgery, radiation, and chemotherapy, are primarily effective for primary tumors and large metastases, with limited efficacy for disseminated micrometastases, and there is a need for new therapeutic agents and diagnostic tools for early detection and targeted treatment.
Innovation Solution
Development of humanized antibodies with specific binding affinity for human kallikrein-2 (hK2) that exhibit enhanced therapeutic ratios, allowing higher radiation doses to be administered with reduced side effects, using engineered antibody polypeptides with optimized CDR sequences and human frameworks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (surgery, radiation, chemotherapy) are used for prostate cancer treatment, then primary tumors and large metastases can be treated, but disseminated micrometastases remain ineffective and healthy tissues suffer collateral damage
Solution Approach 1:
The patent employs radiolabeled antibodies as intermediary agents that specifically bind to hK2 antigens on prostate cancer cells. This targeted approach delivers radiation therapy directly to malignant cells while sparing healthy tissues, resolving the contradiction between effective treatment and reduced collateral damage. The antibody acts as a mediator between the radiation source and the cancer cells, enabling selective destruction of tumor cells.
Solution Approach 2:
The invention utilizes the cancer cells' own hK2 antigen expression as a self-identifying marker. The radiolabeled antibodies exploit this self-expressed antigen to locate and bind to cancer cells autonomously, enabling the treatment system to self-target without requiring external guidance. This self-service mechanism enhances treatment reliability while minimizing damage to healthy tissues that do not express hK2.
2Reliability
If higher radiation doses are administered to improve treatment effectiveness, then tumor control improves, but side effects and damage to healthy tissues increase
Solution Approach 1:
Radiolabeled antibodies serve as intermediaries that carry radiation to tumor cells with high specificity. This enables administration of higher radiation doses to tumors while the antibody mediator prevents excessive radiation exposure to healthy tissues, thus improving tumor control without proportionally increasing side effects.
Solution Approach 2:
The treatment delivers radiation with locally concentrated quality at the tumor site through antibody targeting. The radiation dose is highly localized to cells expressing hK2, creating a local quality difference between tumor and healthy tissues. This allows high radiation doses locally at the tumor while maintaining low doses systemically, improving tumor control without increasing overall side effects.
3Productivity
If existing therapeutic agents are used, then some treatment effect is achieved, but there is limited efficacy for disseminated micrometastases and need for new therapeutic agents
Solution Approach 1:
Radiolabeled antibodies act as intermediaries that can reach and target disseminated micrometastases throughout the body. Unlike surgery which is limited to accessible primary tumors, the antibody mediator can circulate systemically and bind to hK2 on micrometastases anywhere in the body, significantly improving productivity for treating disseminated disease while maintaining high reliability through specific targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The humanized antibodies provide improved tumor-to-bone marrow absorbed dose ratios, enabling more effective treatment of prostate cancer with reduced collateral damage to healthy tissues.
Implementation Method 1
an antibody polypeptide with binding specificity for human kallikrein-2 (hK2)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The disclosure further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer